Method for treating a patient in need of therapy for a neurodegenerative disease by administering to that patient a therapeutically effective dose of a triglyceride oil containing both .gamma.-linolenic acid and linolenic acid residues as triglyceride ester. The ratio of .gamma.-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of .gamma.-linolenic acid residues at the sn-2 position is at least 18%. The oil is administered at a dose sufficient to maintain or elevate TGF-.beta.1 levels in the patient at a therapeutic level.

BTG International Limited

Use of triglyceride oils containing .gamma.-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease

There is provided a pharmaceutical composition for treatment or prevention of a neurodegenerative disease, comprising an RXR agonist as an active ingredient, which is a compound represented by formula (1) or (2). The pharmaceutical composition is effective in treatment or prevention of neurodegenerative diseases such as dementia, Parkinson's disease and multiple sclerosis with reducing side effects such as enlargement of the liver and elevation of blood triglyceride level. In these formulas, A represents CMe.sub.2, N-methyl, N-ethyl or N-isopropyl; X represents N, CH or C--CF.sub.3; Y and Z represent N or CH; R.sup.1 represents methyl, hydroxy, methoxy or ethoxy; R.sup.2 represents H, methyl or ethyl; B represents NR.sup.3 or CHR.sup.3; R.sup.3 represents alkyl; and R.sup.4 represents H, halogen, alkyl, alkenyl, aryl, alkynyl, alkoxy or acyl. ##STR00001##

NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY

Pharmaceutical composition for treatment or prevention of neurodegenerative diseases

The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I). ##STR00001##

Zimmerman; Robert

Zechner; Rudolf

Haemmerle; Gunther

Hofler; Gerald

Das; Suman

Lass; Achim

Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity

The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.

neurodegenerative diseases/triglyceride

Use of triglyceride oils containing .gamma.-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease

Pharmaceutical composition for treatment or prevention of neurodegenerative diseases

Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity

Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism

Täydellisin lääketieteellinen tietokanta tieteen tukemana